Escherichia coli Strain Nissle 1917 Ameliorates Experimental Colitis via Toll-Like Receptor 2- and Toll-Like Receptor 4-Dependent Pathways
暂无分享,去创建一个
B. Wiedenmann | R. Schumann | A. Dignass | B. Raupach | D. Baumgart | D. Paclik | A. Dignass | A. Sturm | U. Sonnenborn | C. Guzy | A. Dankof | Ralf R. Schumann | J. Eckert | A. Grabig | J. Erckenbrecht | Andreas Sturm | D. C. Baumgart
[1] S. Akira,et al. Toll-like receptors and innate immunity , 2006, Journal of Molecular Medicine.
[2] H. S. Warren,et al. Toll-like receptors. , 2005, Critical care medicine.
[3] G. Macfarlane,et al. Toll‐like receptors‐2, ‐3 and ‐4 expression patterns on human colon and their regulation by mucosal‐associated bacteria , 2005, Immunology.
[4] G. T. te Meerman,et al. Association Between Toll‐like Receptor 4 and Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.
[5] H. Qin,et al. Effect of lactobacillus on the gut microflora and barrier function of the rats with abdominal infection. , 2005, World journal of gastroenterology.
[6] A. Zeng,et al. Genomic peculiarity of coding sequences and metabolic potential of probiotic Escherichia coli strain Nissle 1917 inferred from raw genome data. , 2005, Journal of biotechnology.
[7] H. Volk,et al. Probiotic Therapy in the Prevention of Pouchitis Onset: Decreased Interleukin‐1&bgr;, Interleukin‐8, and Interferon‐&ggr; Gene Expression , 2005 .
[8] T. Hibi,et al. Nonpathogenic Escherichia coli Strain Nissle1917 Prevents Murine Acute and Chronic Colitis , 2005, Inflammatory bowel diseases.
[9] E. Cario. BACTERIAL INTERACTIONS WITH CELLS OF THE INTESTINAL MUCOSA: TOLL-LIKE RECEPTORS AND NOD2 , 2005, Gut.
[10] B. Wiedenmann,et al. Escherichia coli Nissle 1917 Distinctively Modulates T-Cell Cycling and Expansion via Toll-Like Receptor 2 Signaling , 2005, Infection and Immunity.
[11] M. Guslandi. Antibiotics for inflammatory bowel disease: do they work? , 2005, European journal of gastroenterology & hepatology.
[12] A. Dignass,et al. Current biological therapies for inflammatory bowel disease. , 2004, Current pharmaceutical design.
[13] K. Michaelsen,et al. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. , 2004, The Journal of pediatrics.
[14] M. Stolte,et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine , 2004, Gut.
[15] J. Jacobberger,et al. Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn’s disease and ulcerative colitis , 2004, Gut.
[16] A. Iwasaki,et al. Toll-like receptor control of the adaptive immune responses , 2004, Nature Immunology.
[17] W. Kruis,et al. Antibiotics and probiotics in inflammatory bowel disease , 2004, Alimentary pharmacology & therapeutics.
[18] G. Gottschalk,et al. Analysis of the Genome Structure of the Nonpathogenic Probiotic Escherichia coli Strain Nissle 1917 , 2004, Journal of bacteriology.
[19] C. Mcnaught,et al. Influence of synbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomised controlled trial. , 2004, Clinical nutrition.
[20] Ruslan Medzhitov,et al. Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis , 2004, Cell.
[21] M. Sans,et al. Inflammatory bowel disease: the role of environmental factors. , 2004, Autoimmunity reviews.
[22] L. Mayer,et al. Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease. , 2004, Gastroenterology.
[23] G. Greenberg. Antibiotics should be used as first-line therapy for Crohn's disease. , 2004, Inflammatory bowel diseases.
[24] R Balfour Sartor,et al. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. , 2004, Gastroenterology.
[25] S. Akira,et al. Toll-Like Receptors Are Temporally Involved in Host Defense , 2004, The Journal of Immunology.
[26] J. Schölmerich,et al. Preventive Effects of Escherichia coli Strain Nissle 1917 on Acute and Chronic Intestinal Inflammation in Two Different Murine Models of Colitis , 2004, Clinical Diagnostic Laboratory Immunology.
[27] S. Akira,et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. , 2004, Gastroenterology.
[28] C. Neut,et al. Self inflicted rectal ulcer: hearing is believing , 2003, Gut.
[29] J. Schölmerich,et al. Rationale for Probiotic and Antibiotic Treatment Strategies in Inflammatory Bowel Diseases , 2003, Digestive Diseases.
[30] Gregor Reid,et al. Potential Uses of Probiotics in Clinical Practice , 2003, Clinical Microbiology Reviews.
[31] U. Göbel,et al. Lipoteichoic Acid (LTA) of Streptococcus pneumoniaeand Staphylococcus aureus Activates Immune Cells via Toll-like Receptor (TLR)-2, Lipopolysaccharide-binding Protein (LBP), and CD14, whereas TLR-4 and MD-2 Are Not Involved* , 2003, The Journal of Biological Chemistry.
[32] B. Wiedenmann,et al. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease , 2003, Alimentary pharmacology & therapeutics.
[33] J. Udagawa,et al. Strategic Compartmentalization of Toll-Like Receptor 4 in the Mouse Gut1 , 2003, The Journal of Immunology.
[34] C. Loddenkemper,et al. Role of Gamma Delta T Cells in Inflammatory Bowel Disease , 2003, Pathobiology.
[35] D. Polk,et al. Probiotic Bacterium Prevents Cytokine-induced Apoptosis in Intestinal Epithelial Cells* , 2002, The Journal of Biological Chemistry.
[36] G. Gottschalk,et al. A Single Nucleotide Exchange in the wzy Gene Is Responsible for the Semirough O6 Lipopolysaccharide Phenotype and Serum Sensitivity of Escherichia coli Strain Nissle 1917 , 2002, Journal of bacteriology.
[37] P. Gionchetti,et al. Treatment of mild to moderate ulcerative colitis and pouchitis , 2002, Alimentary pharmacology & therapeutics.
[38] Jongdae Lee,et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. , 2002, Gastroenterology.
[39] Adrian Ozinsky,et al. Toll-like receptors: key mediators of microbe detection. , 2002, Current opinion in immunology.
[40] S. Akira,et al. Toll-like receptors control activation of adaptive immune responses , 2001, Nature Immunology.
[41] G. Reid,et al. Can bacterial interference prevent infection? , 2001, Trends in microbiology.
[42] U. Göbel,et al. Toll-like Receptor-2 Mediates Treponema Glycolipid and Lipoteichoic Acid-induced NF-κB Translocation* , 2001, The Journal of Biological Chemistry.
[43] P. Brigidi,et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. , 2000, Gastroenterology.
[44] S. Akira,et al. Expression of Toll-Like Receptor 2 on γδ T Cells Bearing Invariant Vγ6/Vδ1 Induced by Escherichia coli Infection in Mice1 , 2000, The Journal of Immunology.
[45] R. Blumberg,et al. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. , 1999, Current opinion in immunology.
[46] S. Akira,et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. , 1999, Immunity.
[47] B. Rembacken,et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial , 1999, The Lancet.
[48] Yoshinori Nagai,et al. MD-2, a Molecule that Confers Lipopolysaccharide Responsiveness on Toll-like Receptor 4 , 1999, The Journal of experimental medicine.
[49] R. N. Smith,et al. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease , 1999, Immunological reviews.
[50] E. Bloemena,et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines , 1998, Clinical and experimental immunology.
[51] G. Jung,et al. Structure and Specific Activity of Macrophage-Stimulating Lipopeptides from Mycoplasma hyorhinis , 1998, Infection and Immunity.
[52] C. Fiocchi. Inflammatory bowel disease: etiology and pathogenesis. , 1998, Gastroenterology.
[53] H A Malchow,et al. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? , 1997, Journal of clinical gastroenterology.
[54] M. Stolte,et al. Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis , 1997, Alimentary pharmacology & therapeutics.
[55] K. Ewe,et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) , 1995, Clinical and experimental immunology.
[56] D. Rachmilewitz,et al. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. , 1995, Gut.
[57] J. Hacker,et al. Properties ofEscherichia coli strains of serotype O6 , 1995, Infection.
[58] M. Leach,et al. Genetic and spontaneous models of inflammatory bowel disease in rodents: evidence for abnormalities in mucosal immune regulation. , 1995, Therapeutic immunology.
[59] T. Klaenhammer,et al. Genetics of bacteriocins produced by lactic acid bacteria. , 1993, FEMS microbiology reviews.
[60] H. Cooper,et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. , 1993, Laboratory investigation; a journal of technical methods and pathology.
[61] L. Vuyst,et al. Bacteriocins of Lactic Acid Bacteria , 1994 .
[62] W. Strober. Animal models of inflammatory bowel disease—An overview , 1985, Digestive Diseases and Sciences.
[63] F. Shanahan,et al. Probiotics: an emerging therapy. , 2005, Current pharmaceutical design.
[64] R. Medzhitov,et al. Toll-like receptors: linking innate and adaptive immunity. , 2004, Microbes and infection.
[65] H. Volk,et al. Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression. , 2005, Inflammatory bowel diseases.
[66] W. Kruis. Review article: antibiotics and probiotics in inflammatory bowel disease. , 2004, Alimentary pharmacology & therapeutics.
[67] Shizuo Akira,et al. MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis , 2004, Journal of Gastroenterology.
[68] A. Sturm,et al. Probiotika bei chronisch entzündlichen Darmerkrankungen , 2003 .
[69] J. Hacker,et al. Development of strain-specific PCR reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples. , 2003, Research in microbiology.
[70] R. Schumann,et al. TLR2: cellular sensor for microbial and endogenous molecular patterns. , 2002, Current topics in microbiology and immunology.
[71] Manfred Dietel,et al. Mucosal flora in inflammatory bowel disease. , 2002, Gastroenterology.
[72] B. Beutler,et al. TLR4 as the mammalian endotoxin sensor. , 2002, Current topics in microbiology and immunology.
[73] P. Godowski,et al. Toll-Like Receptor 2 Ligands as Adjuvants for Human Th1 Responses , 2002 .
[74] S. Akira,et al. Expression of toll-like receptor 2 on gamma delta T cells bearing invariant V gamma 6/V delta 1 induced by Escherichia coli infection in mice. , 2000, Journal of immunology.